Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab plus 2CdA in MALT Lymphoma
NCT00656812Phase 2Completed
- Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
- Start
- May 2008
- Primary completion
- Sep 2011
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab, cladribine in mucosa associated lymphoid tissue lymphoma, sponsored by Arbeitsgemeinschaft medikamentoese Tumortherapie. Started May 2008; status: completed.
02
Drugs
rituximabcladribine
03
Conditions
mucosa associated lymphoid tissue lymphoma
Beyond the preview
Go deeper on NCT00656812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00656812.